BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun W, Zheng A, Miller R, Krammer F, Palese P. An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines (Basel) 2019;7:E117. [PMID: 31540436 DOI: 10.3390/vaccines7030117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Pardi N, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun 2022;13:4677. [PMID: 35945226 DOI: 10.1038/s41467-022-32149-8] [Reference Citation Analysis]
2 Olukitibi TA, Ao Z, Azizi H, Mahmoudi M, Coombs K, Kobasa D, Kobinger G, Yao X. Development and characterization of influenza M2 ectodomain and/or HA stalk-based DC-targeting vaccines for different influenza infections.. [DOI: 10.1101/2021.10.07.463539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Isakova-Sivak I, Stepanova E, Mezhenskaya D, Matyushenko V, Prokopenko P, Sychev I, Wong PF, Rudenko L. Influenza vaccine: progress in a vaccine that elicits a broad immune response. Expert Rev Vaccines 2021;:1-16. [PMID: 34348561 DOI: 10.1080/14760584.2021.1964961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Zeigler DF, Gage E, Clegg CH. Epitope-targeting platform for broadly protective influenza vaccines. PLoS One 2021;16:e0252170. [PMID: 34043704 DOI: 10.1371/journal.pone.0252170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Park BR, Kim KH, Kotomina T, Kim MC, Kwon YM, Jeeva S, Jung YJ, Bhatnagar N, Isakova-Sivak I, Mezhenskaya D, Rudenko L, Wang BZ, Kang SM. Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin. Sci Rep 2021;11:4151. [PMID: 33603072 DOI: 10.1038/s41598-021-83704-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
6 Kotomina T, Isakova-Sivak I, Kim KH, Park BR, Jung YJ, Lee Y, Mezhenskaya D, Matyushenko V, Kang SM, Rudenko L. Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes. Vaccines (Basel) 2020;8:E648. [PMID: 33153089 DOI: 10.3390/vaccines8040648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Tang S, Zhu W, Wang BZ. Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches. Viruses 2020;12:E1212. [PMID: 33114336 DOI: 10.3390/v12111212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses 2020;12:E1033. [PMID: 32957468 DOI: 10.3390/v12091033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
9 Kim KH, Jung YJ, Lee Y, Park BR, Oh J, Lee YN, Kim MC, Jeeva S, Kang SM. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope. Virology 2020;550:51-60. [PMID: 32882637 DOI: 10.1016/j.virol.2020.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]